Sjoerd van der Burg
Hoogleraar
- Naam
- Prof.dr. S.H. van der Burg
- Telefoon
- +31 71 526 1180
- s.h.van_der_burg@lumc.nl
- ORCID iD
- 0000-0002-6556-0354
Sjoerd van der Burg is hoogleraar in de Immunotherapie van solide tumoren, in het bijzonder immunomonitoring. Hij is hoofd van het laboratorium Medische Oncologie en leider van de groep Experimentele Kanker Immunologie en Therapie. Tevens is hij aangesteld als senior onderzoeker bij het Oncode Instituut.
Meer informatie over Sjoerd van der Burg
Zie ook
Het afweersysteem en kanker
Het afweersysteem speelt een essentiële maar duale rol bij de ontwikkeling van kanker. De bestudering van de interactie tussen tumor en afweersysteem in diermodellen en patiënten met kanker of voorstadia hiervan leidt tot een beter begrip over de rol van de verschillende componenten van het afweersysteem de tumorgroei ondersteunen of juist tegen gaan. Dit begrip vormt de basis voor de ontwikkeling van diverse vormen van immunotherapie, gericht op het versterken van de tumor-reactieve afweer als behandeling van kanker. Het onderzoek levert een belangrijke bijdrage aan het beantwoorden van de cluster vragen 85, 96, en 99 binnen de Nederlandse Wetenschap Agenda.
Wetenschappelijke carrière
Van der Burg verkreeg zijn doctoraat op 1 April 1998 voor zijn proefschrift getiteld “Identification and evaluation of cytotoxic T-cell epitopes in HIV-1 and tumour associated proteins” van de Universiteit van Leiden.
In 2003 werd hij aangesteld als staflid (LUMC) en Universitair Docent (Leiden University) bij de afdeling Immunohematologie en Bloed Transfusie.
In 2006 werd hij aangesteld als staflid (LUMC) en Universitair Hoofddocent (Leiden University) en leider van de groep “Experimentele kankerimmunologie en therapie” bij de afdeling Medische Oncologie, LUMC.
In 2010 werd hij aangesteld als Hoogleraar bij de afdeling Medische Oncologie, LUMC. Hij sprak zijn oratie, getiteld “Op zoek naar een éénarmige immunoloog” uit op 9 Mei 2011.
In 2019 werd hij tevens aangesteld als Senior Investigator bij het Oncode Instituut.
Hoogleraar
- Faculteit Geneeskunde
- Divisie 4
- Klinische Oncologie
- Klinische Oncologie algemeen
- Poelgeest, M.I.E. van; Kortekaas, K.E.; Doorn, H.C. van; Oonk, M.; Nijman, H.W.; Boere, I.; Eerkens, A.L.; Reyners, A.; Ewing-Graham, P.C.; Bart, J.; Welters, M.J.P.; Bosse, T.; Kroep, J.R. & Burg, S.H. van der (2024), APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma, International Journal of Gynecological Cancer.
- Lei, X.; Groot, D.C. de; Welters, M.J.P.; Wit, T. de; Schrama, E.; Eenennaam, H. van; Santegoets, S.J.; Oosenbrug, T.; Veen, A. van der; Vos, J.L.; Zuur, C.L.; Miranda, N.F.C.C. de; Jacobs, H.; Burg, S.H. van der; Borst, J. & Xiao, Y.L. (2024), CD4+T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors, Cellular & Molecular Immunology.
- Santegoets, S.J.; Stolk, A.; Welters, M.J.P. & Burg, S.H. van der (2023), The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival, Cell Reports Medicine 4(11).
- Eijck, C.W.F. van; Koning, W. de; Sijde, F. van der; Moskie, M.; Koerkamp, B.G.; Homs, M.Y.V.; Burg, S.H. van der; Eijck, C.H.J. van & Mustafa, D.A.M. (2023), A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma, European Journal of Cancer 181: 119-134.
- Verdegaal, E.M.E.; Santegoets, S.J.; Welters, M.J.P.; Bruin, L. de; Visser, M.; Minne, C.E. van der; Kok, P.M. de; Loof, N.M.; Boekestijn, S.; Roozen, I.; Westra, I.M.; Meij, P.; Burg, S.H. van der & Kroep, J.R. (2023), Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer, Journal for ImmunoTherapy of Cancer 11(11).
- Middelburg, J.; Ghaffari, S.; Schoufour, T.A.W.; Sluijter, M.; Schaap, G.; Göynük, B.; Sala, B.M.; Al-Tamimi, L.; Scheeren, F.; Franken, K.L.M.C.; Akkermans, J.J.L.L.; Cabukusta, B.; Joosten, S.A.; Derksen, I.; Neefjes, J.; Burg, S.H. van der; Achour, A.; Wijdeven, R.H.M.; Weidanz, J. & Hall, T. van (2023), The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent, Cell Reports 42(12).
- Gulijk, M. van; Krimpen, A. van; Schetters, S.; Eterman, M.; Elsas, M. van; Mankor, J.; Klaase, L.; Bruijn, M. de; Nimwegen, M. van; Tienhoven, T. van; Ijcken, W. van; Boon, L.; Schoot, J. van der; Verdoes, M.; Scheeren, F.; Burg, S.H. van der; Lambrecht, B.N.; Stadhouders, R.; Dammeijer, F.; Aerts, J. & Hall, T. van (2023), PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance, Science Immunology 8(83).
- Lybaert, L.; Thielemans, K.; Feldman, S.A.; Burg, S.H. van der; Bogaert, C. & Ott, P.A. (2023), Neoantigen-directed therapeutics in the clinic: where are we?, TRENDS IN CANCER 98(6): 503-519.
- Groeneveldt, C.; Ginkel, J.Q.; Kinderman, P.; Sluijter, M.; Griffioen, L.; Labrie, C.; Wollenberg, D.J.M. van den; Hoeben, R.C.; Burg, S.H. van der; Dijke, P. ten; Hawinkels, L.J.A.C.; Hall, T. van & Montfoort, N. van (2023), Intertumoral differences dictate the outcome of TGF-β blockade on the efficacy of viro-immunotherapy, Cancer Research Communications 3(2): 325-337.
- Eijck, C.W.F. van; Mustafa, D.A.M.; Vadgama, D.; Miranda, N.F.C.C. de; Koerkamp, B.G.; Tienhoven, G. van; Burg, S.H. van der; Malats, N.; Eijck, C.H.J. van & Dutch Pancreatic Canc Grp DPCG (2023), Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer, Gut 73.
- Lybaert, L.; Lefever, S.; Fant, B.; Smits, E.; Geest, B. de; Breckpot, K.; Dirix, L.; Feldman, S.A.; Criekinge, W. van; Thielemans, K.; Burg, S.H. van der; Ott, P.A. & Bogaert, C. (2023), Challenges in neoantigen-directed therapeutics, Cancer Cell 41(1): 15-40.
- Haake, M.; Haack, B.; Schäfer, T.; Harter, P.N.; Mattavelli, G.; Eiring, P.; Vashist, N.; Wedekink, F.; Genssler, S.; Fischer, B.; Dahlhoff, J.; Mokhtari, F.; Kuzkina, A.; Welters, M.J.P.; Benz, T.M.; Sorger, L.; Thiemann, V.; Almanzar, G.; Selle, M.; Thein, K.; Späth, J.; Gonzalez, M.C.; Reitinger, C.; Ipsen-Escobedo, A.; Wistuba-Hamprecht, K.; Eichler, K.; Filipski, K.; Zeiner, P.S.; Beschorner, R.; Goedemans, R.; Gogolla, F.H.; Hackl, H.; Rooswinkel, R.W.; Thiem, A.; Roche, P.R.; Joshi, H.; Pühringer, D.; Wöckel, A.; Diessner, J.E.; Rüdiger, M.; Leo, E.; Cheng, P.F.; Levesque, M.P.; Goebeler, M.; Sauer, M.; Nimmerjahn, F.; Schuberth-Wagner, C.; Felten, S. von; Mittelbronn, M.; Mehling, M.; Beilhack, A.; Burg, S.H. van der; Riedel, A.; Weide, B.; Dummer, R. & Wischhusen, J. (2023), Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment, Nature Communications 14(1).
- Elsas, M.J. van; Labrie, C.; Etzerodt, A.; Charoentong, P.; Thans, J.J.C.V.; Hall, T. van & Burg, S.H. van der (2023), Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy, Journal for ImmunoTherapy of Cancer 11(3).
- Bulk, J. van den; Ploeg, M. van der; Ijsselsteijn, M.E.; Ruano, D.; Breggen, R. van der; Duhen, R.; Peeters, K.C.M.J.; Farina-Sarasqueta, A.; Verdegaal, E.M.E.; Burg, S.H. van der; Duhen, T. & Miranda, N.F.C.C. de (2023), CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden, Journal for ImmunoTherapy of Cancer 11(2).
- Abdulrahman, Z.; Santegoets, S.J.; Sturm, G.; Charoentong, P.; Ijsselsteijn, M.E.; Somarakis, A.; Hollt, T.; Finotello, F.; Trajanoski, Z.; Egmond, S.L. van; Mustafa, D.A.M.; Welters, M.J.P.; Miranda, N.F.C.C. de & Burg, S.H. van der (2022), Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival, Journal for ImmunoTherapy of Cancer 10(2).
- Lau, S.P.; Land, F.R. van 't; Burg, S.H. van der; Homs, M.Y.V.; Lolkema, M.P.; Aerts, J.G.J.V. & Eijck, C.H.J. van (2022), Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer, BMJ Open 12(6).
- Groeneveldt, C.; Kinderman, P.; Thans, J.J.C.V.; Labrie, C.; Griffioen, L.; Sluijter, M.; Wollenberg, D.J.M. van den; Hoeben, R.C.; Haan, J.M.M. den; Burg, S.H. van der; Hall, T. van & Montfoort, N. van (2022), Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy, United European Gastroenterology Journal 10.
- Elsas, M.J. van; Schoot, J.M.S. van der; Bartels, A.; Steuten, K.; Dalen, D. van; Wijfjes, Z.; Figdor, C.G.; Hall, T. van; Burg, S.H. van der; Verdoes, M. & Scheeren, F.A. (2022), Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody, International Journal of Molecular Sciences 23(15).
- Lau, S.P.; Land, F.R. van 't; Burg, S.H. van der; Homs, M.Y.V.; Lolkema, M.P.; Aerts, J.G.J.V. & Eijck, C.H.J. van (2022), Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer, BMJ Open 12(6).
- Speetjens, F.M.; Welters, M.J.P.; Slingerland, M.; Poelgeest, M.I.E. van; Steenwijk, P.J.D. van; Roozen, I.; Boekestijn, S.; Loof, N.M.; Zom, G.G.; Valentijn, A.R.P.M.; Krebber, W.J.; Meeuwenoord, N.J.; Janssen, C.A.H.; Melief, C.J.M.; Marel, G.A. van der; Filippov, D.V.; Burg, S.H. van der; Gelderblom, H. & Ossendorp, F. (2022), Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions, Journal for ImmunoTherapy of Cancer 10(10).
- Abdulrahman, Z.; Hendriks, N.; Kruse, A.J.; Somarakis, A.; Sande, A.J.M. van de; Beekhuizen, H.J. van; Piek, J.M.J.; Miranda, N.F.C.C. de; Kooreman, L.F.S.; Slangen, B.F.M.; Burg, S.H. van der; Steenwijk, P.J.D. van & Esch, E.M.G. van (2022), Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions, Journal for ImmunoTherapy of Cancer 10(11).
- Gruil, N. de; Pijl, H.; Burg, S.H. van der & Kroep, J.R. (2022), Short-term fasting synergizes with solid cancer therapy by boosting antitumor immunity, Cancers 14(6).
- Santegoets, S.J.; Welters, M.J.P.; Schrikkema, D.S.; Freriks, M.R.; Kok, H.; Weissbrich, B.; Branden, A. van den; Linnemann, C.; Schumacher, T.N.; Adhikary, S.; Bendle, G. & Burg, S.H. van der (2022), The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer, Cancer Immunology, Immunotherapy 72.
- Gezgin, G.; Visser, M.; Ruano, D.; Santegoets, S.J.; Miranda, N.F.C.C. de; Velden, P.A. van der; Luyten, G.P.M.; Burg, S.H. van der; Verdegaal, E.M. & Jager, M.J. (2022), Tumor-infiltrating T cells can be expanded successfully from primary uveal melanoma after separation from their tumor environment, OPHTHALMOLOGY SCIENCE 2(2).
- Borst, L.; Sluijter, M.; Sturm, G.; Charoentong, P.; Santegoets, S.J.; Gulijk, M.; Elsas, M.J. van; Groeneveldt, C.; Montfoort, N. van; Finotello, F.; Trajanoski, Z.; Kielbasa, S.M.; Burg, S.H. van der & Hall, T. van (2022), NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division, International Journal of Cancer 150(4): 688-704.
- Duurland, C.L.; Santegoets, S.J.; Abdulrahman, Z.; Loof, N.M.; Sturm, G.; Wesselink, T.H.; Arens, R.; Boekestijn, S.; Ehsan, I.; Poelgeest, M.I.E. van; Finotello, F.; Hackl, H.; Trajanoski, Z.; Dijke, P. ten; Braud, V.M.; Welters, M.J.P. & Burg, S.H. van der (2022), CD161 expression and regulation defines rapidly responding effector CD4+T cells associated with improved survival in HPV16-associated tumors, Journal for ImmunoTherapy of Cancer 10(1).
- Wu, S.D.; Rietveld, M.; Hogervorst, M.; Gruijl, F. de; Burg, S. van der; Vermeer, M.; Doorn, R. van; Welters, M. & Ghalbzouri, A. el (2022), Human papillary and reticular fibroblasts show distinct functions on tumor behavior in 3D-organotypic cultures mimicking melanoma and HNSCC, International Journal of Molecular Sciences 23(19).
- Harryvan, T.J.; Visser, M.; Bruin, L. de; Plug, L.; Griffioen, L.; Mulder, A.; Veelen, P.A. van; Noort, G.J.V. van; Jongsma, M.L.; Meeuwsen, M.H.; Wiertz, E.J.; Santegoets, S.J.; Hardwick, J.C.; Hall, T. van; Neefjes, J.; Burg, S.H. van der; Hawinkels, L.J.A.C. & Verdegaal, E.M.E. (2022), Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S, Journal for ImmunoTherapy of Cancer 10(3).
- Cuburu, N.; Finn, O.J. & Burg, S.H. van der (2022), Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines, Frontiers in Immunology 13.
- Stingl, C.; Lau, S.P.; Burg, S.H. van der; Aerts, J.G.; Eijck, C.H.J. van & Luider, T.M. (2022), Dataset from a proteomics analysis of tumor antigens shared between an allogenic tumor cell lysate vaccine and pancreatic tumor tissue., Data in Brief 44.
- Duijn, A. van; Burg, S.H. van der & Scheeren, F.A. (2022), CD47/SIRPα axis: bridging innate and adaptive immunity, Journal for ImmunoTherapy of Cancer 10(7).
- Pasmans, H.; Berkowska, M.A.; Diks, A.M.; Mooij, B. de; Groenland, R.J.; Rond, L. de; Nicolaie, M.A.; Burg, S.H. van der; Dongen, J.J.M. van; Klis, F.R.M. van der & Buisman, A.M. (2022), Characterization of the early cellular immune response induced by HPV vaccines, Frontiers in Immunology 13.
- Duijn, A. van; Burg, S.H. van der & Scheeren, F.A. (2022), CD47/SIRP alpha axis: bridging innate and adaptive immunity, Journal for ImmunoTherapy of Cancer 10(7).
- Paaso, A.; Koskimaa, H.M.; Welters, M.J.P.; Kero, K.; Rautava, J.; Syrjanen, K.; Burg, S.H. van der & Syrjanen, S. (2021), Interferon-gamma and IL-5 associated cell-mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa, Clinical and Experimental Dental Research 7(5).
- Saxena, M.; Burg, S.H. van der; Melief, C.J.M. & Bhardwaj, N. (2021), Therapeutic cancer vaccines, Nature Reviews Cancer 21(6): 360-378.
- Otterhaug, T.; Janetzki, S.; Welters, M.J.P.; Hakerud, M.; Nedberg, A.G.; Edwards, V.T.; Boekestijn, S.; Loof, N.M.; Selbo, P.K.; Olivecrona, H.; Burg, S.H. van der & Hogset, A. (2021), Photochemical internalization enhanced vaccination is safe, and gives promising cellular immune responses to an HPV peptide-based vaccine in a phase I clinical study in healthy volunteers, Frontiers in Immunology 11.
- Marijt, K.A.; Griffioen, L.; Blijleven, L.; Burg, S.H. van der & Hall, T. van (2021), Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement, Cancer Immunology, Immunotherapy 71.
- Melssen, M.M.; Lindsay, R.S.; Stasiak, K.; Rodriguez, A.B.; Briegel, A.M.; Cyranowski, S.; Rutkowski, M.R.; Conaway, M.R.; Melief, C.J.M.; Burg, S.H. van der; Eyo, U.; Slingluff, C.L. & Engelhard, V.H. (2021), Differential expression of CD49a and CD49b determines localization and function of tumor-infiltrating CD8(+) T cells, Cancer Immunology Research 9(5): 583-597.
- Nejad, E.B.; Labrie, C.; Elsas, M.J. van; Kleinovink, J.W.; Mittrucker, H.W.; Franken, K.L.M.C.; Heink, S.; Korn, T.; Arens, R.; Hall, T. van & Burg, S.H. van der (2021), IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors, Journal for ImmunoTherapy of Cancer 9(4).
- Burg, S.H. van der (2021), IL11: A Specific Repressor of Tumor-Specific CD4(+) T Cells, Cancer Immunology Research 9(7): 724-724.
- Corbeau, A.; Nout, R.A.; Mens, J.W.M.; Horeweg, N.; Godart, J.; Kerkhof, E.M.; Kuipers, S.C.; Poelgeest, M.I.E. van; Kroep, J.R.; Boere, I.A.; Doorn, H.C. van; Hoogeman, M.S.; Heide, U.A. van der; Putter, H.; Welters, M.J.P.; Burg, S.H. van der; Creutzberg, C.L. & Boer, S.M. de (2021), PROTECT: prospective phase-II-trial evaluating adaptive proton therapy for cervical cancer to reduce the impact on morbidity and the immune system, Cancers 13(20).
- Kortekaas, K.E.; Santegoets, S.J.; Tas, L.; Ehsan, I.; Charoentong, P.; Doorn, H.C. van; Poelgeest, M.I.E. van; Mustafa, D.A.M. & Burg, S.H. van der (2021), Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy, Journal for ImmunoTherapy of Cancer 9(10).
- Baltussen, J.C.; Welters, M.J.P.; Verdegaal, E.M.E.; Kapiteijn, E.; Schrader, A.M.R.; Slingerland, M.; Liefers, G.J.; Burg, S.H. van der; Portielje, J.E.A. & Glas, N.A. de (2021), Predictive biomarkers for outcomes of immune checkpoint inhibitors (ICIs) in melanoma: a systematic review, Cancers 13(24).
- Verdegaal, E.; Kooij, M.K. van der; Visser, M.; Minne, C. van der; Bruin, L. de; Meij, P.; Scheltinga, A.T. van; Welters, M.J.; Santegoets, S.; Miranda, N. de; Roozen, I.; Liefers, G.J.; Kapiteijn, E. & Burg, S.H. van der (2020), Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies, Journal for ImmunoTherapy of Cancer 8(1).
- Groeneveldt, C.; Kinderman, P.; Wollenberg, D.J.M. van den; Oever, R.L. van den; Middelburg, J.; Mustafa, D.A.M.; Hoeben, R.C.; Burg, S.H. van der; Hall, T. van & Montfoort, N. van (2020), Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy, Journal for ImmunoTherapy of Cancer 8(2).
- Kortekaas, K.E.; Bastiaannet, E.; Doorn, H.C. van; Steenwijk, P.J.D. van; Ewing-Graham, P.C.; Creutzberg, C.L.; Akdeniz, K.; Nooij, L.S.; Burg, S.H. van der; Bosse, T. & Poelgeest, M.I.E. van (2020), Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes, Gynecologic Oncology 159(3): 649-656.
- Welters, M.J.P.; Santegoets, S.J. & Burg, S.H. van der (2020), The tumor microenvironment and immunotherapy of oropharyngeal squamous cell carcinoma, Frontiers in Oncology 10.
- Ende, T.C. van den; Heuts, J.M.M.; Gential, G.P.P.; Visser, M.; Graaff, M.J. van de; Ho, N.I.; Jiskoot, W.; Valentijn, A.R.P.M.; Meeuwenoord, N.J.; Overkleeft, H.S.; Codee, J.D.C.; Burg, S.H. van der; Verdegaal, E.M.E.; Marel, G.A. van der; Ossendorp, F. & Filippov, D.V. (2020), Simplified monopalmitoyl toll-like receptor 2 ligand mini-U pam for self-adjuvanting neoantigen-based synthetic cancer vaccines, ChemBioChem 22(7).
- Kooij, M.K. van der; Verdegaal, E.M.E.; Visser, M.; Bruin, L. de; Minne, C.E. van der; Meij, P.M.; Roozen, I.C.F.M.; Jonker, M.A.; Bosch, S. van den; Liefers, G.J.; Speetjens, F.M.; Burg, S.H. van der & Kapiteijn, E. (2020), Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial, BMJ Open 10(11).
- Hurkmans, D.P.; Verdegaal, E.M.E.; Hogan, S.A.; Wijn, R. de; Hovestad, L.; Heuvel, D.M.A. van den; Ruijtenbeek, R.; Welters, M.J.P.; Brakel, M. van; Basak, E.A.; Pinedo, H.M.; Lamers, C.H.J.; Werken, H.J.G. van de; Groten, J.P.; Debets, R.; Levesque, M.P.; Dummer, R.; Kapiteijn, E.; Mathijssen, R.H.J.; Aerts, J.G.J.V. & Burg, S.H. van der (2020), Blood-based kinase activity profiling, Journal for ImmunoTherapy of Cancer 8(2).
- Borst, L.; Burg, S.H. van der & Hall, T. van (2020), The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment, Clinical Cancer Research 26(21): 5549-5556.
- Jong, G. de; Bartels, L.; Kedde, M.; Verdegaal, E.M.E.; Gillissen, M.A.; Levie, S.E.; Cercel, M.G.; Hal-van Veen, S.E. van; Fatmawati, C.; Berg, D. van de; Yasuda, E.; Claassen, Y.B.; Bakker, A.Q.; Burg, S.H. van der; Schotte, R.; Villaudy, J.; Spits, H.; Hazenberg, M.D.; Helden, P.M. van & Wagner, K. (2020), Melanoma cells can be eliminated by sialylated CD43 x CD3 bispecific T cell engager formats in vitro and in vivo, Cancer Immunology, Immunotherapy.
- Nejad, E.B.; Labrie, C.; Abdulrahman, Z.; Elsas, M.J. van; Rademaker, E.; Kleinovink, J.W.; Sluis, T.C. van der; Duikeren, S. van; Teunisse, A.F.A.S.; Jochemsen, A.G.; Oosting, J.; Miranda, N.F.C.C. de; Hall, T. van; Arens, R. & Burg, S.H. van der (2020), Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy, Journal for ImmunoTherapy of Cancer 8(2).
- Elsas, M. van; Kleinovink, J.W.; Moerland, M.; Feiss, G.; Beyrend, G.; Arens, R.; Mei, H.L.; Nibbering, P.H.; Jirka, S.M.; Hall, T. van & Burg, S.H. van der (2020), Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models, Journal for ImmunoTherapy of Cancer 8(2).
- Kortekaas, K.E.; Santegoets, S.J.; Sturm, G.; Ehsan, I.; Egmond, S.L. van; Finotello, F.; Trajanoski, Z.; Welters, M.J.P.; Poelgeest, M.I.E. van & Burg, S.H. van der (2020), CD39 Identifies the CD4(+) Tumor-Specific T-cell Population in Human Cancer, Cancer Immunology Research 8(10): 1311-1321.
- Hurkmans, D.P.; Kuipers, M.E.; Smit, J.; Marion, R. van; Mathijssen, R.H.J.; Postmus, P.E.; Hiemstra, P.S.; Aerts, J.G.J.V.; Thusen, J.H. von der & Burg, S.H. van der (2020), Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients, Cancer Immunology, Immunotherapy 69(5): 771-777.
- Melief, C.J.M.; Welters, M.J.P.; Vergote, I.; Kroep, J.R.; Kenter, G.G.; Ottevanger, P.B.; Tjalma, W.A.A.; Denys, H.; Poelgeest, M.I.E. van; Nijman, H.W.; Reyners, A.K.L.; Velu, T.; Goffin, F.; Lalisang, R.I.; Loof, N.M.; Boekestijn, S.; Krebber, W.J.; Hooftman, L.; Visscher, S.; Blumenstein, B.A.; Stead, R.B.; Gerritsen, W. & Burg, S.H. van der (2020), Strong vaccine responses during chemotherapy are associated with prolonged cancer survival, Science Translational Medicine 12(535).
- Nejad, E.B.; Labrie, C.; Sluis, T.C. van der; Duikeren, S. van; Franken, K.L.M.C.; Roosenhoff, R.; Arens, R.; Hall, T. van & Burg, S.H. van der (2020), Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function, International Journal of Cancer 148(1).
- Bidmon, N.; Gouttefangeas, C.; Burg, S.H. van der; Galluzzi, L. & Rudqvist, N.P. (2020), Generation of TCR-engineered reference cell samples to control T-cell assay performance, Methods in Enzymology 631: 195-221.
- Lau, S.P.; Montfoort, N. van; Kinderman, P.; Lukkes, M.; Klaase, L.; Nimwegen, M. van; Gulijk, M. van; Dumas, J.; Mustafa, D.A.M.; Lievense, S.L.A.; Groeneveldt, C.; Stadhouders, R.; Li, Y.L.; Stubbs, A.; Marijt, K.A.; Vroman, H.; Burg, S.H. van der; Aerts, J.; Hall, T. van; Dammeijer, F. & Eijck, C.H.J. van (2020), Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model, Journal for ImmunoTherapy of Cancer 8(2).
- Abdulrahman, Z.; Miranda, N.F.C.C. de; Hellebrekers, B.W.J.; Steenwijk, P.J.D. van; Esch, E.M.G. van; Burg, S.H. van der & Poelgeest, M.I.E. van (2020), A pre-existing coordinated inflammatory microenvironment is associated with complete response of vulvar high-grade squamous intraepithelial lesions to different forms of immunotherapy, International Journal of Cancer 147(10): 2914-2923.
- Abdulrahman, Z.; Miranda, N. de; Esch, E.M.G. van; Steenwijk, P.J.D. van; Nijman, H.W.; Welters, M.J.P.; Poelgeest, M.I.E. van & Burg, S.H. van der (2020), Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination, Journal for ImmunoTherapy of Cancer 8(1).
- Groeneveldt, C.; Hall, T. van; Burg, S.H. van der; Dijke, P. ten & Montfoort, N. van (2020), Immunotherapeutic Potential of TGF-beta Inhibition and Oncolytic Viruses, Trends in Immunology 41(5): 406-420.
- Santegoets, S.J.; Duurland, C.L.; Jordanova, E.J.; Ham, V.J. van; Ehsan, I.; Loof, N.M.; Narang, V.; Dutertre, C.A.; Ginhoux, F.; Egmond, S.L. van; Welters, M.J.P. & Burg, S.H. van der (2020), CD163(+)cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer, Journal for ImmunoTherapy of Cancer 8(2).
- Elsas, M.J. van; Hall, T. van & Burg, S.H. van der (2020), Future challenges in cancer resistance to immunotherapy, Cancers 12(4).
- Hilf, N.; Kuttruff-Coqui, S.; Frenzel, K.; Bukur, V.; Stevanovic, S.; Gouttefangeas, C.; Platten, M.; Tabatabai, G.; Dutoit, V.; Burg, S.H. van der; Straten, P.T.; Martinez-Ricarte, F.; Ponsati, B.; Okada, H.; Lassen, U.; Admon, A.; Ottensmeier, C.H.; Ulges, A.; Kreiter, S.; Deimling, A. von; Skardelly, M.; Migliorini, D.; Kroep, J.R.; Idorn, M.; Rodon, J.; Piro, J.; Poulsen, H.S.; Shraibman, B.; McCann, K.; Mendrzyk, R.; Lower, M.; Stieglbauer, M.; Britten, C.M.; Capper, D.; Welters, M.J.P.; Sahuquillo, J.; Kiesel, K.; Derhovanessian, E.; Rusch, E.; Bunse, L.; Song, C.; Heesch, S.; Wagner, C.; Kemmer-Bruck, A.; Ludwig, J.; Castle, J.C.; Schoor, O.; Tadmor, A.D.; Green, E.; Fritsche, J.; Meyer, M.; Pawlowski, N.; Dorner, S.; Hoffgaard, F.; Rossler, B.; Maurer, D.; Weinschenk, T.; Reinhardt, C.; Huber, C.; Rammensee, H.G.; Singh-Jasuja, H.; Sahin, U.; Dietrich, P.Y. & Wick, W. (2019), Actively personalized vaccination trial for newly diagnosed glioblastoma, Nature 565(7738): 240-+.
- Massarelli, E.; William, W.; Johnson, F.; Kies, M.; Ferrarotto, R.; Guo, M.; Feng, L.; Lee, J.J.; Tran, H.; Kim, Y.U.; Haymaker, C.; Bernatchez, C.; Curran, M.; Barrese, T.Z.; Canales, J.R.; Wistuba, I.; Li, L.R.; Wang, J.; Burg, S.H. van der; Melief, C.J. & Glisson, B. (2019), Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial, JAMA Oncology 5(1): 67-73.
- Nejad, E.B.; Ratts, R.B.; Panagioti, E.; Meyer, C.; Oduro, J.D.; Cicin-Sain, L.; Fruh, K.; Burg, S.H. van der & Arens, R. (2019), Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection, Journal for ImmunoTherapy of Cancer 7.
- Santegoets, S.J.; Duurland, C.L.; Jordanova, E.S.; Ham, J.J. van; Ehsan, I.; Egmond, S.L. van; Welters, M.J.P. & Burg, S.H. van der (2019), Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1T cell responses, Journal for ImmunoTherapy of Cancer 7.
- Santegoets, S.J.; Ham, V.J. van; Ehsan, I.; Charoentong, P.; Duurland, C.L.; Unen, V. van; Hollt, T.; Velden, L.A. van der; Egmond, S.L. van; Kortekaas, K.E.; Steenwijk, P.J.D. van; Poelgeest, M.E.I.E. van; Welters, M.J.P. & Burg, S.H. van der (2019), The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival, Clinical Cancer Research 25(1): 240-252.
- Hanoteau, A.; Newton, J.M.; Krupar, R.; Huang, C.; Liu, H.C.; Gaspero, A.; Gartrell, R.D.; Saenger, Y.M.; Hart, T.D.; Santegoets, S.J.; Laoui, D.; Spanos, C.; Parikh, F.; Jayaraman, P.; Zhang, B.; Burg, S.H. van der; Ginderachter, J.A. van; Melief, C.J.M. & Sikora, A.G. (2019), Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy, Journal for ImmunoTherapy of Cancer 7.
- Bulk, J. van den; Verdegaal, E.M.E.; Ruano, D.; Ijsselsteijn, M.E.; Visser, M.; Breggen, R. van der; Duhen, T.; Ploeg, M. van der; Vries, N.L. de; Oosting, J.; Peeters, K.C.M.J.; Weinberg, A.D.; Farina-Sarasqueta, A.; Burg, S.H. van der & Miranda, N.F.C.C. de (2019), Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4, Genome Medicine 11(1).
- Wierenga, A.P.A.; Cao, J.F.; Mouthaan, H.; Weeghel, C. van; Verdijk, R.M.; Duinen, S.G. van; Kroes, W.G.M.; Dogrusoz, M.; Marinkovic, M.; Burg, S.S.H. van der; Luyten, G.P.M. & Jager, M.J. (2019), Aqueous Humor Biomarkers Identify Three Prognostic Groups in Uveal Melanoma, Investigative Ophthalmology & Visual Science 60(14): 4740-4747.
- Kortekaas, K.E.; Santegoets, S.J.; Abdulrahman, Z.; Ham, V.J. van; Tol, M. van der; Ehsan, I.; Doom, H.C. van; Bosse, T.; Poelgeest, M.I.E. van & Burg, S.H. van der (2019), High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status, Journal for ImmunoTherapy of Cancer 7(1).
- Pasmans, H.; Schurink-van't Klooster, T.M.; Bogaard, M.J.M.; Rooijen, D.M. van; Melker, H.E. de; Welters, M.J.P.; Burg, S.H. van der; Klis, F.R.M. van der & Buisman, A.M. (2019), Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls, Vaccine 37(49): 7280-7288.
- Souri, Z.; Wierenga, A.P.A.; Weeghel, C. van; Velden, P.A. van der; Kroes, W.G.M.; Luyten, G.P.M.; Burg, S.H. van der; Jochemsen, A.G. & Jager, M.J. (2019), Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma, Cancers 11(8).
- Marijt, K.A.; Sluijter, M.; Blijleven, L.; Tolmeijer, S.H.; Scheeren, F.A.; Burg, S.H. van der & Hall, T. van (2019), Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFN gamma receptor signaling, Journal for ImmunoTherapy of Cancer 7.
- Hall, T. van; Andre, P.; Horowitz, A.; Ruan, D.F.; Borst, L.; Zerbib, R.; Narni-Mancinelli, E.; Burg, S.H. van der & Vivier, E. (2019), Monalizumab: inhibiting the novel immune checkpoint NKG2A, Journal for ImmunoTherapy of Cancer 7(1).
- Groot, A.F. de; Blok, E.J.; Charehbili, A.; Engels, C.C.; Smit, V.T.H.B.M.; Dekker-Ensink, N.G.; Putter, H.; Kranenbarg, E.M.K.; Velde, C.J.H. van de; Liefers, G.J.; Nortier, J.W.R.; Kuppen, P.J.K.; Burg, S.H. van der & Kroep, J.R. (2019), Strong CD8+lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy, Breast Cancer Research and Treatment 175(3): 605-615.
- Harryvan, T.J.; Verdegaal, E.M.E.; Hardwick, J.C.H.; Hawinkels, L.J.A.C. & Burg, S.H. van der (2019), Targeting of the Cancer-Associated Fibroblast-T-Cell Axis in Solid Malignancies, Journal of Clinical Medicine 8(11).
- Marijt, K.A.; Burg, S.H. van der & Hall, T. van (2019), TEIPP peptides: exploration of unTAPped cancer antigens, OncoImmunology.
- Kooij, M.K. van der; Speetjens, F.M.; Burg, S.H. van der & Kapiteijn, E. (2019), Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types, Cancers 11(6).
- Hung, S.C.; Hou, T.Y.; Jiang, W.; Wang, N.; Qiao, S.W.; Chow, I.T.; Liu, X.; Burg, S.H. van der; Koelle, D.M.; Kwok, W.W.; Sollid, L.M. & Mellins, E.D. (2019), Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense, Journal of Immunology 202(9): 2558-2569.
- Bulk, J. van den; Ruano, D.; IJsselsteijn, M.E.; Visser, M.; Breggen, R. van der; Peeters, K.; Duhen, T.; Duhen, R.; Weinberg, A.D.; Burg, S.H. van der; Verdegaal, E.M.E. & Miranda, N.F. de (2019), Harnessing the immunotherapy revolution for the treatment of colorectal cancer: neo-antigens and beyond, Medicine 98(26).
- Chatterjee, S.; Kang, S.D.; Alam, S.; Salzberg, A.C.; Milici, J.; Burg, S.H. van der; Freeman, W. & Meyers, C. (2019), Tissue-Specific Gene Expression during Productive Human Papillomavirus 16 Infection of Cervical, Foreskin, and Tonsil Epithelium, Journal of Virology 93(17).
- Bidmon, N.; Kind, S.; Welters, M.J.P.; Joseph-Pietras, D.; Laske, K.; Maurer, D.; Hadrup, S.R.; Schreibelt, G.; Rae, R.; Sahin, U.; Gouttefangeas, C.; Britten, C.M. & Burg, S.H. van der (2018), Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance, Journal of Immunological Methods 458: 74-82.
- Kang, S. do; Chatterjee, S.; Alam, S.; Salzberg, A.C.; Milici, J.; Burg, S.H. van der & Meyers, C. (2018), Effect of Productive Human Papillomavirus 16 Infection on Global Gene Expression in Cervical Epithelium, Journal of Virology 92(20).
- Ma, W.B.; Concha-Benavente, F.; Santegoets, S.J.A.M.; Welters, M.J.P.; Ehsan, I.; Ferris, R.L. & Burg, S.H. van der (2018), EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer, PLoS ONE 13(9).
- Panagioti, E.; Klenerman, P.; Lee, L.N.; Burg, S.H. van der & Arens, R. (2018), Features of effective T Cell-inducing vaccines against Chronic viral infections, Frontiers in Immunology 9.
- Marijt, K.A.; Blijleven, L.; Verdegaal, E.M.E.; Kester, M.G.; Kowalewski, D.J.; Rammensee, H.G.; Stevanovic, S.; Heemskerk, M.H.M.; Burg, S.H. van der & Hall, T. van (2018), Identification of non-mutated neoantigens presented by TAP-deficient tumors, Journal of Experimental Medicine 215(9): 2325-2337.
- Shraibman, B.; Barnea, E.; Kadosh, D.M.; Haimovich, Y.; Slobodin, G.; Rosner, I.; Lopez-Larrea, C.; Hilf, N.; Kuttruff, S.; Song, C.; Britten, C.; Castle, J.; Kreiter, S.; Frenzel, K.; Tatagiba, M.; Tabatabai, G.; Dietrich, P.Y.; Dutoit, V.; Wick, W.; Platten, M.; Winkler, F.; Deimling, A. von; Kroep, J.; Sahuquillo, J.; Martinez-Ricarte, F.; Rodon, J.; Lassen, U.; Ottensmeier, C.; Burg, S.H. van der; Straten, P. thor; Poulsen, H.S.; Ponsati, B.; Okada, H.; Rammensee, H.G.; Sahin, U.; Singh, H. & Admon, A. (2018), Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma, Molecular and Cellular Proteomics 17(11): 2132-2145.
- Santegoets, S.J.A.M.; Groot, A.F. de; Dijkgraaf, E.M.; Simoes, A.M.C.; Noord, V.E. van der; Ham, J.J. van; Welters, M.J.P.; Kroep, J.R. & Burg, S.H. van der (2018), The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival, OncoImmunology 7(8).
- Abdulrahman, Z.; Kortekaas, K.E.; Steenwijk, P.J.D. van; Burg, S.H. van der & Poelgeest, M.I.E. van (2018), The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy, Expert Opinion on Biological Therapy 18(12): 1223-1233.
- Gezgin G., Visser M., van der Burg S. H., Verdegaal E. M. & Jager M. J. (2018), Tumor-infiltrating lymphocytes in primary uveal melanoma, Acta Ophthalmologica 96: 46-47.
- Montfoort, N. van; Borst, L.; Korrer, M.J.; Sluijter, M.; Marijt, K.A.; Santegoets, S.J.; Ham, V.J. van; Ehsan, I.; Charoentong, P.; Andre, P.; Wagtmann, N.; Welters, M.J.P.; Kim, Y.J.; Piersma, S.J.; Burg, S.H. van der & Hall, T. van (2018), NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines, Cell 175(7): 1744-+.
- Lange, M.J. de; Nell, R.J.; Lalai, R.N.; Versluis, M.; Jordanova, E.S.; Luyten, G.P.M.; Jager, M.J.; Burg, S.H. van der; Zoutman, W.H.; Hall, T. van & Velden, P.A. van der (2018), Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma, Molecular Cancer Research 16(12): 1902-1911.
- Burg, S.H. van der (2018), Correlates of immune and clinical activity of novel cancer vaccines, Seminars in Immunology 39(C): 119-136.
- Groot, A.F. de; Appelman-Dijkstra, N.M.; Burg, S.H. van der & Kroep, J.R. (2018), The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review, Cancer Treatment Reviews 62: 18-28.
- Doorduijn, E.M.; Sluijter, M.; Marijt, K.A.; Querido, B.J.; Burg, S.H. van der & Hall, T. van (2018), T cells specific for a TAP-independent self-peptide remain naive in tumor-bearing mice and are fully exploitable for therapy, OncoImmunology 7(3).
- Welters, M.J.P.; Ma, W.B.; Santegoets, S.J.A.M.; Goedemans, R.; Ehsan, I.; Jordanova, E.S.; Ham, V.J. van; Unen, V. van; Koning, F.; Egmond, S.I. van; Charoentong, P.; Trajanoski, Z.; Velden, L.A. van der & Burg, S.H. van der (2018), Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer, Clinical Cancer Research 24(3): 634-647.
- Doorduijn, E.M.; Sluijter, M.; Querido, B.J.; Seidel, U.J.E.; Oliveira, C.C.; Burg, S.H. van der & Hall, T. van (2018), T cells engaging the conserved Mhc class ib Molecule Qa-1(b) with TaP-independent Peptides are semi-invariant lymphocytes, Frontiers in Immunology 9.
- Melief, S.M.; Visconti, V.V.; Visser, M.; Diepen, M. van; Kapiteijn, E.H.W.; Berg, J.H. van den; Haanen, J.B.A.G.; Smit, V.T.H.B.M.; Oosting, J.; Burg, S.H. van der & Verdegaal, E.M.E. (2017), Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature, Cancer Immunology Research 5(2): 170-179.
- Nejad, E.B.; Welters, M.J.P.; Arens, R. & Burg, S.H. van der (2017), The importance of correctly timing cancer immunotherapy, Expert Opinion on Biological Therapy 17(1): 87-103.
- Doorduijn, E.M.; Sluijter, M.; Salvatori, D.C.; Silvestri, S.; Maas, S.; Arens, R.; Ossendorp, F.; Burg, S.H. van der & Hall, T. van (2017), CD4(+) T Cell and NK Cell Interplay Key to Regression of MHC Class I-low Tumors upon TLR7/8 Agonist Therapy, Cancer Immunology Research 5(8): 642-653.
- Ma, W.B.; Melief, C.J.M. & Burg, S.H. van der (2017), Control of immune escaped human papilloma virus is regained after therapeutic vaccination, Current Opinion in Virology 23: 16-22.
- Panagioti, E.; Boon, L.; Arens, R. & Burg, S.H. van der (2017), Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4(+) and CD8(+) T Cell Responses against Mouse Cytomegalovirus Infection, Frontiers in Immunology 8.
- Gezgin, G.; Dogrusoz, M.; Essen, T.H. van; Kroes, W.G.M.; Luyten, G.P.M.; Velden, P.A. van der; Walter, V.; Verdijk, R.M.; Hall, T. van; Burg, S.H. van der & Jager, M.J. (2017), Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment, Cancer Immunology, Immunotherapy 66(7): 903-912.
- Samuels, S.; Heeren, A.M.; Zijlmans, H.J.M.A.A.; Welters, M.J.P.; Berg, J.H. van den; Philips, D.; Kvistborg, P.; Ehsan, I.; Scholl, S.M.E.; Nuijen, B.; Schumacher, T.N.M.; Beurden, M. van; Jordanova, E.S.; Haanen, J.B.A.G.; Burg, S.H. van der & Kenter, G.G. (2017), HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia, Cancer Immunology, Immunotherapy 66(9): 1163-1173.
- Melief, S.M.; Visser, M.; Burg, S.H. van der & Verdegaal, E.M.E. (2017), IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma, Cancer Immunology, Immunotherapy 66(7): 913-926.
- Meir, H. van; Nout, R.A.; Welters, M.J.P.; Loof, N.M.; Kam, M.L. de; Ham, J.J. van; Samuels, S.; Kenter, G.G.; Cohen, A.F.; Melief, C.J.M.; Burggraaf, J.; Poelgeest, M.I.E. van & Burg, S.H. van der (2017), Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients, OncoImmunology 6(2).
- Dammeijer, F.; Lau, S.P.; Eijck, C.H.J. van; Burg, S.H. van der & Aerts, J.G.J.V. (2017), Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors, Cytokine & Growth Factor Reviews 36: 5-15.
- Cao, J.F.; Heijkants, R.C.; Jochemsen, A.G.; Dogrusoz, M.; Lange, M.J. de; Velden, P.A. van der; Burg, S.H. van der; Jager, M.J. & Verdijk, R.M. (2017), Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy, Oncotarget 8(35): 58021-58036.
- Meir, H. van; Burck, I.J. du; Kam, M.L. de; Welters, M.J.P.; Burg, S.H. van der; Trimbos, J.B.M.Z.; Kroon, C.D. de & Poelgeest, M.I.E. van (2017), The identification of patients at high risk for recurrent disease after treatment for early-stage cervical cancer, European Journal of Gynaecological Oncology 38(1): 25-32.
- Verdegaal, E.M.E. & Burg, S.H. van der (2017), The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy, Frontiers in Immunology 8.
- Koskimaa, H.M.; Paaso, A.; Welters, M.J.P.; Grenman, S.; Syrjanen, K.; Burg, S.H. van der & Syrjanen, S. (2017), The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization, European Journal of Clinical Microbiology and Infectious Diseases 36(8): 1491-1503.
- Burg, S.H. van der; Arens, R.; Ossendorp, F.; Hall, T. van & Melief, A.J.M. (2016), Vaccines for established cancer: overcoming the challenges posed by immune evasion, Nature Reviews Cancer 16(4): 219-233.
- Poelgeest, M.I.E. van; Welters, M.J.P.; Vermeij, R.; Stynenbosch, L.F.M.; Loof, N.M.; Berends-van der Meer, D.M.A.; Lowik, M.J.G.; Hamming, I.L.E.; Esch, E.M.G. van; Hellebrekers, B.W.J.; Beurden, M. van; Schreuder, H.W.; Kagie, M.J.; Trimbos, J.B.M.Z.; Fathers, L.M.; Daemen, T.; Hollema, H.; Valentijn, A.R.P.M.; Oostendorp, J.; Oude Elberink, H.N.G.; Fleuren, G.J.; Bosse, T.; Kenter, G.G.; Stijnen, T.; Nijman, H.W.; Melief, C.J.M. & Burg, S.H. van der (2016), Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response, Clinical Cancer Research 22(10): 2342-2350.
- Nejad, E.B.; Sluis, T.C. van der; Duikeren, S. van; Yagita, H.; Janssen, G.M.; Veelen, P.A. van; Melief, C.J.M.; Burg, S.H. van der & Arens, R. (2016), Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8(+) T Cells, Cancer Research 76(20): 6017-6029.
- Burg, S.H. van der & Marincola, F. (2016), Editorial overview: Tumour immunology: What's beyond, today's success in tumor immunology, Current Opinion in Immunology 39: VIII-X.
- Doorduijn, E.M.; Sluijter, M.; Querido, B.J.; Oliveira, C.C.; Achour, A.; Ossendorp, F.; Burg, S.H. van der & Hall, T. van (2016), TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors, Journal of Clinical Investigation 126(2): 784-794.
- Yazdi, M.T.; Riet, S. van; Schadewijk, A. van; Fiocco, M.; Hall, T. van; Taube, C.; Hiemstra, P.S. & Burg, S.H. van der (2016), The positive prognostic effect of stromal CD8+tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma, Oncotarget 7(3): 3467-3478.
- Welters, M.J.; Sluis, T.C. van der; Meir, H. van; Loof, N.M.; Ham, V.J. van; Duikeren, S. van; Santegoets, S.J.; Arens, R.; Kam, M.L. de; Cohen, A.F.; Poelgeest, M.I. van; Kenter, G.G.; Kroep, J.R.; Burggraaf, J.; Melief, C.J. & Burg, S.H. van der (2016), Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses, Science Translational Medicine 8(334).
- Mandruzzato, S.; Brandau, S.; Britten, C.M.; Bronte, V.; Damuzzo, V.; Gouttefangeas, C.; Maurer, D.; Ottensmeier, C.; Burg, S.H. van der; Welters, M.J.P. & Walter, S. (2016), Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study, Cancer Immunology, Immunotherapy 65(2): 161-169.
- Zom, G.G.; Welters, M.J.P.; Loof, N.M.; Goedemans, R.; Lougheed, S.; Valentijn, R.R.P.M.; Zandvliet, M.L.; Meeuwenoord, N.J.; Melief, C.J.M.; Gruijl, T.D. de; Marel, G.A. van der; Filippov, D.V.; Ossendorp, F. & Burg, S.H. van der (2016), TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients, Oncotarget 7(41): 67087-67100.
- Panagioti, E.; Redeker, A.; Duikeren, S. van; Franken, K.L.M.C.; Drijfhout, J.W.; Burg, S.H. van der & Arens, R. (2016), The Breadth of Synthetic Long Peptide Vaccine-Induced CD8(+) T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection, PLoS Pathogens 12(9).
- Poelgeest, M.I.E. van; Visconti, V.V.; Aghai, Z.; Ham, V.J. van; Heusinkveld, M.; Zandvliet, M.L.; Valentijn, A.R.P.M.; Goedemans, R.; Minne, C.E. van der; Verdegaal, E.M.E.; Trimbos, J.B.M.Z.; Burg, S.H. van der & Welters, M.J.P. (2016), Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer, Cancer Immunology, Immunotherapy 65(12): 1451-1463.
- Santegoets, S.J.A.M.; Welters, M.J.P. & Burg, S.H. van der (2016), Monitoring of the Immune Dysfunction in Cancer Patients, Vaccines 4(3).
- Yazdi, M.T.; Schinkelshoek, M.S.; Loof, N.M.; Taube, C.; Hiemstra, P.S.; Welters, M.J.P. & Burg, S.H. van der (2016), Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer, OncoImmunology 5(12).
- Verdegaal, E.M.E.; Miranda, N.F.C.C. de; Visser, M.; Harryvan, T.; Buuren, M.M. van; Andersen, R.S.; Hadrup, S.R.; Minne, C.E. van der; Schotte, R.; Spits, H.; Haanen, J.B.A.G.; Kapiteijn, E.H.W.; Schumacher, T.N. & Burg, S.H. van der (2016), Neoantigen landscape dynamics during human melanoma-T cell interactions, Nature 536(7614): 91-+.
- Ma, W.B.; Tummers, B.; Esch, E.M.G. van; Goedemans, R.; Melief, C.J.M.; Meyers, C.; Boer, J.M. & Burg, S.H. van der (2016), Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFN gamma- and TNF alpha-Mediated Antiproliferative Effects and Necroptosis, Frontiers in Immunology 7.
- Mellman, I.; Hubbard-Lucey, V.M.; Tontonoz, M.J.; Kalos, M.D.; Chen, D.S.; Allison, J.P.; Drake, C.G.; Levitsky, H.; Lonberg, N.; Burg, S.H. van der; Fearon, D.T.; Wherry, E.J.; Lowy, I.; Vonderheide, R.H. & Hwu, P. (2016), De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute, Cancer Immunology Research 4(4): 279-288.
- Punt, S.; Dronkers, E.A.C.; Welters, M.J.P.; Goedemans, R.; Koljenovic, S.; Bloemena, E.; Snijders, P.J.F.; Gorter, A.; Burg, S.H. van der; Jong, R.J.B. de & Jordanova, E.S. (2016), A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency, Cancer Immunology, Immunotherapy 65(4): 393-403.
- Hadrup, S.R.; Maurer, D.; Laske, K.; Frosig, T.M.; Andersen, S.R.; Britten, C.M.; Burg, S.H. van der; Walter, S. & Gouttefangeas, C. (2015), Cryopreservation of MHC Multimers: Recommendations for Quality Assurance in Detection of Antigen Specific T Cells, Cytometry Part A 87A(1): 37-48.
- Dijkgraaf, E.M.; Santegoets, S.J.A.M.; Reyners, A.K.L.; Goedemans, R.; Nijman, H.W.; Poelgeest, M.I.E. van; Erkel, A.R. van; Smit, V.T.H.B.M.; Daemen, T.A.H.H.; Hoeven, J.J.M. van der; Melief, C.J.M.; Welters, M.J.P.; Kroep, J.R. & Burg, S.H. van der (2015), A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer, Oncotarget 6(31): 32228-32243.
- Dijkgraaf, E.M.; Santegoets, S.J.A.M.; Reyners, A.K.L.; Goedemans, R.; Wouters, M.C.A.; Kenter, G.G.; Erkel, A.R. van; Poelgeest, M.I.E. van; Nijman, H.W.; Hoeven, J.J.M. van der; Welters, M.J.P.; Burg, S.H. van der & Kroep, J.R. (2015), A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha 2b in patients with recurrent epithelial ovarian cancer, Annals of Oncology 26(10): 2141-2149.
- Rosalia, R.A.; Cruz, L.J.; Duikeren, S. van; Tromp, A.T.; Silva, A.L.; Jiskoot, W.; Gruijl, T. de; Lowik, C.; Oostendorp, J.; Burg, S.H. van der & Ossendorp, F. (2015), CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses, Biomaterials 40: 88-97.
- Apetoh, L.; Smyth, M.J.; Drake, C.G.; Abastado, J.P.; Apte, R.N.; Ayyoub, M.; Blay, J.Y.; Bonneville, M.; Butterfield, L.H.; Caignard, A.; Castelli, C.; Cavallo, F.; Celis, E.; Chen, L.P.; Colombo, M.P.; Comin-Anduix, B.; Coukos, G.; Dhodapkar, M.V.; Dranoff, G.; Frazer, I.H.; Fridman, W.H.; Gabrilovich, D.I.; Gilboa, E.; Gnjatic, S.; Jager, D.; Kalinski, P.; Kaufman, H.L.; Kiessling, R.; Kirkwood, J.; Knuth, A.; Liblau, R.; Lotze, M.T.; Lugli, E.; Marincola, F.; Melero, I.; Melief, C.J.; Mempel, T.R.; Mittendorf, E.A.; Odun, K.; Overwijk, W.W.; Palucka, A.K.; Parmiani, G.; Ribas, A.; Romero, P.; Schreiber, R.D.; Schuler, G.; Srivastava, P.K.; Tartour, E.; Valmori, D.; Burg, S.H. van der; Bruggen, P. van der; Eynde, B.J. van den; Wang, E.; Zou, W.P.; Whiteside, T.L.; Speiser, D.E.; Pardoll, D.M.; Restifo, N.P. & Anderson, A.C. (2015), Consensus nomenclature for CD8(+) T cell phenotypes in cancer, OncoImmunology 4(4).
- Vogel, C.J.; Smit, M.A.; Maddalo, G.; Possik, P.A.; Sparidans, R.W.; Burg, S.H. van der; Verdegaal, E.M.; Heck, A.J.R.; Samatar, A.A.; Beijnen, J.H.; Altelaar, A.F.M. & Peeper, D.S. (2015), Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK, Pigment Cell and Melanoma Research 28(3).
- Gouttefangeas, C.; Chan, C.; Attig, S.; Kollgaard, T.T.; Rammensee, H.G.; Stevanovic, S.; Wernet, D.; Straten, P.T.; Welters, M.J.P.; Ottensmeier, C.; Burg, S.H. van der & Britten, C.M. (2015), Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters, Cancer Immunology, Immunotherapy 64(5): 585-598.
- Bidmon, N.; Attig, S.; Rae, R.; Schroder, H.; Omokoko, T.A.; Simon, P.; Kuhn, A.N.; Kreiter, S.; Sahin, U.; Gouttefangeas, C.; Burg, S.H. van der & Britten, C.M. (2015), Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays, Journal of Immunology 194(12): 6177-6189.
- Tummers, B. & Burg, S.H. van der (2015), High-Risk Human Papillomavirus Targets Crossroads in Immune Signaling, Viruses 7(5): 2485-2506.
- Linnemann, C.; Buuren, M.M. van; Bies, L.; Verdegaal, E.M.E.; Schotte, R.; Calis, J.J.A.; Behjati, S.; Velds, A.; Hilkmann, H.; Atmioui, D. el; Visser, M.; Stratton, M.R.; Haanen, J.B.A.G.; Spits, H.; Burg, S.H. van der & Schumacher, T.N.M. (2015), High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma, Nature Medicine 21(1): 81-85.
- Koskimaa, H.M.; Paaso, A.; Welters, M.J.P.; Grenman, S.; Syrjanen, K.; Burg, S.H. van der & Syrjanen, S. (2015), Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative, Journal of Translational Medicine 13.
- Yazdi, M.T.; Loof, N.M.; Franken, K.L.M.C.; Taube, C.; Oostendorp, J.; Hiemstra, P.S.; Welters, M.J.P. & Burg, S.H. van der (2015), Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma, Cancer Immunology, Immunotherapy 64(9): 1109-1121.
- Santegoets, S.J.A.M.; Dijkgraaf, E.M.; Battaglia, A.; Beckhove, P.; Britten, C.M.; Gallimore, A.; Godkin, A.; Gouttefangeas, C.; Gruijl, T.D. de; Koenen, H.J.P.M.; Scheffold, A.; Shevach, E.M.; Staats, J.; Tasken, K.; Whiteside, T.L.; Kroep, J.R.; Welters, M.J.P. & Burg, S.H. van der (2015), Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry, Cancer Immunology, Immunotherapy 64(10): 1271-1286.
- Sluis, T.C. van der; Burg, S.H. van der; Arens, R. & Melief, C.J.M. (2015), New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer, Current Opinion in Immunology 35: 9-14.
- Sluis, T.C. van der; Burg, S.H. van der & Melief, C.J.M. (2015), Synergy between chemotherapy and cancer vaccination, Aging 7(6): 340-341.
- Tummers, B.; Goedemans, R.; Pelascini, L.P.L.; Jordanova, E.S.; Esch, E.M.G. van; Meyers, C.; Melief, C.J.M.; Boer, J.M. & Burg, S.H. van der (2015), The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NF kappa B activation, Nature Communications 6.
- Melief, C.J.M.; Hall, T. van; Arens, R.; Ossendorp, F. & Burg, S.H. van der (2015), Therapeutic cancer vaccines, Journal of Clinical Investigation 125(9): 3401-3412.
- Sluis, T.C. van der; Sluijter, M.; Duikeren, S. van; West, B.L.; Melief, C.J.M.; Arens, R.; Burg, S.H. van der & Hall, T. van (2015), Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression, Cancer Immunology Research 3(9): 1042-1051.
- Gorter, A.; Prins, F.; Diepen, M. van; Punt, S. & Burg, S.H. van der (2015), The tumor area occupied by Tbet plus cells in deeply invading cervical cancer predicts clinical outcome, Journal of Translational Medicine 13.
- Sluis, T.C. van der; Duikeren, S. van; Huppelschoten, S.; Jordanova, E.S.; Nejad, E.B.; Sloots, A.; Boon, L.; Smit, V.T.H.B.M.; Welters, M.J.P.; Ossendorp, F.; Water, B. van de; Arens, R.; Burg, S.H. van der & Melief, C.J.M. (2015), Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death, Clinical Cancer Research 21(4): 781-794.
- Lange, M.J. de; Pelt, S.I. van; Versluis, M.; Jordanova, E.S.; Kroes, W.G.M.; Ruivenkamp, C.; Burg, S.H. van der; Luyten, G.P.M.; Hall, T. van; Jager, M.J. & Velden, P.A. van der (2015), Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma, Oncotarget 6(35): 37824-37835.
- Esch, E.M.G. van; Poelgeest, M.I.E. van; Kouwenberg, S.; Osse, E.M.; Trimbos, J.B.M.Z.; Fleuren, G.J.; Jordanova, E.S. & Burg, S.H. van der (2015), Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival, International Journal of Cancer 136(4): E95-E106.
- Esch, E.M.G. van; Poelgeest, M.I.E. van; Trimbos, J.B.M.Z.; Fleuren, G.J.; Jordanova, E.S. & Burg, S.H. van der (2015), Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia, International Journal of Cancer 136(4): E85-E94.
- Gezgin, G.; Bronkhorst, I.H.G.; Essen, T.H. van; Pelt, S. van; Verdijk, R.M.; Velden, P.A. van der; Luyten, G.P.M.; Hall, T. van; Burg, S.H. van der & Jager, M.J. (2015), Loss of BAPI expression is associated with increased angiogenesis in uveal melanoma, Investigative Ophthalmology & Visual Science 56(7).
- Esch, E.M.G. van; Tummers, B.; Baartmans, V.; Osse, E.M.; Haar, N. ter; Trietsch, M.D.; Hellebrekers, B.W.J.; Holleboom, C.A.G.; Nagel, H.T.C.; Tan, L.T.; Fleuren, G.J.; Poelgeest, M.I.E. van; Burg, S.H. van der & Jordanova, E.S. (2014), Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy, International Journal of Cancer 135(4): 830-842.
- Wouters, M.C.A.; Dijkgraaf, E.M.; Kuijjer, M.L.; Jordanova, E.S.; Hollema, H.; Welters, M.J.P.; Hoeven, J.J.M. van der; Daemen, T.; Kroep, J.R.; Nijman, H.W. & Burg, S. van der (2014), Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.
- Burg, S.H. van der; Sluis, T.C. van der; Meir, H. van; Kroep, J.R.; Kenter, G.G.; Poelgeest, M.I.E. van; Burggraaf, K.; Melief, C.J.M. & Welters, M.J.P. (2014), Synergistic effects of properly timed HPV16 synthetic long peptide vaccination during standard carboplatin-paclitaxel chemotherapy in animals and in patients with metastatic cervical carcinoma, Cancer Research 74(19).
- Galluzzi, L.; Vacchelli, E.; Bravo-San Pedro, J.M.; Buque, A.; Senovilla, L.; Baracco, E.E.; Bloy, N.; Castoldi, F.; Abastado, J.P.; Agostinis, P.; Apte, R.N.; Aranda, F.; Ayyoub, M.; Beckhove, P.; Blay, J.Y.; Bracci, L.; Caignard, A.; Castelli, C.; Cavallo, F.; Celis, E.; Cerundolo, V.; Clayton, A.; Colombo, M.P.; Coussens, L.; Dhodapkar, M.V.; Eggermont, A.M.; Fearon, D.T.; Fridman, W.H.; Fucikova, J.; Gabrilovich, D.I.; Galon, J.; Garg, A.; Ghiringhelli, F.; Giaccone, G.; Gilboa, E.; Gnjatic, S.; Hoos, A.; Hosmalin, A.; Jager, D.; Kalinski, P.; Karre, K.; Kepp, O.; Kiessling, R.; Kirkwood, J.M.; Klein, E.; Knuth, A.; Lewis, C.E.; Liblau, R.; Lotze, M.T.; Lugli, E.; Mach, J.P.; Mattei, F.; Mavilio, D.; Melero, I.; Melief, C.J.; Mittendorf, E.A.; Moretta, L.; Odunsi, A.; Okada, H.; Palucka, A.K.; Peter, M.E.; Pienta, K.J.; Porgador, A.; Prendergast, G.C.; Rabinovich, G.A.; Restifo, N.P.; Rizvi, N.; Sautes-Fridman, C.; Schreiber, H.; Seliger, B.; Shiku, H.; Silva-Santos, B.; Smyth, M.J.; Speiser, D.E.; Spisek, R.; Srivastava, P.K.; Talmadge, J.E.; Tartour, E.; Burg, S.H. van der; Eynde, B.J. van den; Vile, R.; Wagner, H.; Weber, J.S.; Whiteside, T.L.; Wolchok, J.D.; Zitvogel, L.; Zou, W.P. & Kroemer, G. (2014), Classification of current anticancer immunotherapies, Oncotarget 5(24): 12472-12508.
- Kvistborg, P.; Philips, D.; Kelderman, S.; Hageman, L.; Ottensmeier, C.; Joseph-Pietras, D.; Welters, M.J.P.; Burg, S. van der; Kapiteijn, E.; Michielin, O.; Romano, E.; Linnemann, C.; Speiser, D.; Blank, C.; Haanen, J.B. & Schumacher, T.N. (2014), Anti-CTLA-4 therapy broadens the melanoma-reactive CD8(+) T cell response, Science Translational Medicine 6(254).
- Tummers, B.; Goedemans, R.; Jha, V.; Meyers, C.; Melief, C.J.M.; Burg, S.H. van der & Boer, J.M. (2014), CD40-Mediated Amplification of Local Immunity by Epithelial Cells Is Impaired by HPV, Journal of Investigative Dermatology 134(12): 2918-2927.
- Oliveira, C.C.; Sluijter, M.; Querido, B.; Ossendorp, F.; Burg, S.H. van der & Hall, T. van (2014), Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire, Molecular Immunology 62(1): 129-136.
- Bronkhorst, I.H.G.; Jehs, T.M.L.; Dijkgraaf, E.M.; Luyten, G.P.M.; Velden, P.A. van der; Burg, S.H. van der & Jager, M.J. (2014), Effect of Hypoxic Stress on Migration and Characteristics of Monocytes in Uveal Melanoma, JAMA Ophthalmology 132(5): 614-621.
- Chudley, L.; McCann, K.J.; Coleman, A.; Cazaly, A.M.; Bidmon, N.; Britten, C.M.; Burg, S.H. van der; Gouttefangeas, C.; Jandus, C.; Laske, K.; Maurer, D.; Romero, P.; Schroder, H.; Stynenbosch, L.F.M.; Walter, S.; Welters, M.J.P. & Ottensmeier, C.H. (2014), Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining, Cancer Immunology, Immunotherapy 63(11): 1199-1211.
- Koskimaa, H.M.; Paaso, A.E.; Welters, M.J.P.; Grenman, S.E.; Syrjanen, K.J.; Burg, S.H. van der & Syrjanen, S.M. (2014), Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort, Journal of Translational Medicine 12.
- Sluijter, M.; Sluis, T.C. van der; Velden, P.A. van der; Versluis, M.; West, B.L.; Burg, S.H. van der & Hall, T. van (2014), Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy, PLoS ONE 9(8).
- Kaplon, J.; Homig-Holzel, C.; Gao, L.D.; Meissl, K.; Verdegaal, E.M.E.; Burg, S.H. van der; Doorn, R. van & Peeper, D.S. (2014), Near-genomewide RNAi screening for regulators of BRAFV600E-induced senescence identifies RASEF, a gene epigenetically silenced in melanoma, Pigment Cell and Melanoma Research 27(4).
- Yazdi, M.T.; Keene, K.R.; Hiemstra, P.S. & Burg, S.H. van der (2014), Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer, Expert Review of Vaccines 13(1): 87-116.
- Steenwijk, P.J.D. van; Poelgeest, M.I.E. van; Ramwadhdoebe, T.H.; Lowik, M.J.G.; Berends-van der Meer, D.M.A.; Minne, C.E. van der; Loof, N.M.; Stynenbosch, L.F.M.; Fathers, L.M.; Valentijn, A.R.P.M.; Oostendorp, J.; Osse, E.M.; Fleuren, G.J.; Nooij, L.; Kagie, M.J.; Hellebrekers, B.W.J.; Melief, C.J.M.; Welters, M.J.P.; Burg, S.H. van der & Kenter, G.G. (2014), The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study, Cancer Immunology, Immunotherapy 63(2): 147-160.
- Meir, H. van; Kenter, G.G.; Burggraaf, J.; Kroep, J.R.; Welters, M.J.P.; Melief, C.J.M.; Burg, S.H. van der & Poelgeest, M.I.E. van (2014), The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy, Anti-Cancer Agents in Medicinal Chemistry 14(2): 190-203.
- Janetzki, S.; Britten, C.M.; Davis, M.M.; Hoos, A.; Huber, C.; Kalos, M.; Levitsky, H.I.; Maecker, H.T.; Melief, C.J.M.; O'Donnell-Tormey, J.; Odunsi, K.; Old, L.; Ottensmeier, C.; Roep, B.O.; Romero, P.; Burg, S. van der; Walter, S. & MIATA Core Team (2014), The role of the reporting framework MIATA within current efforts to advance immune monitoring, Journal of Immunological Methods 409: 6-8.
- Lampen, M.H.; Hassan, C.; Sluijter, M.; Geluk, A.; Dijkman, K.; Tjon, J.M.; Ru, A.H. de; Burg, S.H. van der; Veelen, P.A. van & Hall, T. van (2013), Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2, Molecular Immunology 53(1-2): 126-131.
- Steenwijk, P.J.D. van; Ramwadhdoebe, T.H.; Goedemans, R.; Doorduijn, E.M.; Ham, J.J. van; Gorter, A.; Hall, T. van; Kuijjer, M.L.; Poelgeest, M.I.E. van; Burg, S.H. van der & Jordanova, E.S. (2013), Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.
- Poelgeest, M.I.E. van; Welters, M.J.P.; Esch, E.M.G. van; Stynenbosch, L.F.M.; Kerpershoek, G.; Meerten, E.L.V. van; Hende, M. van den; Lowik, M.J.G.; Berends-van der Meer, D.M.A.; Fathers, L.M.; Valentijn, A.R.P.M.; Oostendorp, J.; Fleuren, G.J.; Melief, C.J.M.; Kenter, G.G. & Burg, S.H. van der (2013), HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial, Journal of Translational Medicine 11.
- Oliveira, C.C.; Querido, B.; Sluijter, M.; Groot, A.F. de; Zee, R. van der; Rabelink, M.J.W.E.; Hoeben, R.C.; Ossendorp, F.; Burg, S.H. van der & Hall, T. van (2013), New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation, Journal of Immunology 191(8): 4020-4028.
- Singh, S.K.; Tummers, B.; Schumacher, T.N.; Gomez, R.; Franken, K.L.M.C.; Verdegaal, E.M.; Laske, K.; Gouttefangeas, C.; Ottensmeier, C.; Welters, M.J.P.; Britten, C.M. & Burg, S.H. van der (2013), The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study, Cancer Immunology, Immunotherapy 62(3): 489-501.
- Filbert, H.; Attig, S.; Bidmon, N.; Renard, B.Y.; Janetzki, S.; Sahin, U.; Welters, M.J.P.; Ottensmeier, C.; Burg, S.H. van der; Gouttefangeas, C. & Britten, C.M. (2013), Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols, Cancer Immunology, Immunotherapy 62(4): 615-627.
- Arens, R.; Hall, T. van; Burg, S.H. van der; Ossendorp, F. & Melief, C.J.M. (2013), Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer, Seminars in Immunology 25(2): 182-190.
- Oosterhoff, D.; Heusinkveld, M.; Lougheed, S.M.; Kosten, I.; Lindstedt, M.; Bruijns, S.C.M.; Es, T. van; Kooyk, Y. van; Burg, S.H. van der & Gruijl, T.D. de (2013), Intradermal Delivery of TLR Agonists in a Human Explant Skin Model: Preferential Activation of Migratory Dendritic Cells by Polyribosinic-Polyribocytidylic Acid and Peptidoglycans, Journal of Immunology 190(7): 3338-3345.
- Karim, R.; Tummers, B.; Meyers, C.; Biryukov, J.L.; Alam, S.; Backendorf, C.; Jha, V.; Offringa, R.; Ommen, G.J.B. van; Melief, C.J.M.; Guardavaccaro, D.; Boer, J.M. & Burg, S.H. van der (2013), Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune Response, PLoS Pathogens 9(5).
- Rosalia, R.A.; Silva, A.L.; Camps, M.; Allam, A.; Jiskoot, W.; Burg, S.H. van der; Ossendorp, F. & Oostendorp, J. (2013), Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles, Cancer Immunology, Immunotherapy 62(7): 1161-1173.
- Cron, A.; Gouttefangeas, C.; Frelinger, J.; Lin, L.; Singh, S.K.; Britten, C.M.; Welters, M.J.P.; Burg, S.H. van der; West, M. & Chan, C. (2013), Hierarchical Modeling for Rare Event Detection and Cell Subset Alignment across Flow Cytometry Samples, PLoS Computational Biology 9(7).
- Gao, L.; Smit, M.A.; Oord, J.J. van den; Goeman, J.J.; Verdegaal, E.M.E.; Burg, S.H. van der; Stas, M.; Beck, S.; Gruis, N.A.; Tensen, C.P.; Willemze, R.; Peeper, D.S. & Doorn, R. van (2013), Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma, Pigment Cell and Melanoma Research 26(4).
- Gao, L.; Smit, M.; Oord, J. van den; Goeman, J.; Verdegaal, E.; Burg, S. van der; Stas, M.; Beck, S.; Gruis, N.; Tensen, C.; Willemze, R.; Peeper, D. & Doorn, R. van (2013), Comprehensive promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma, Journal of Investigative Dermatology 133: S228-S228.
- Dijkgraaf, E.M.; Heusinkveld, M.; Tummers, B.; Vogelpoel, L.T.C.; Goedemans, R.; Jha, V.; Nortier, J.W.R.; Welters, M.J.P.; Kroep, J.R. & Burg, S.H. van der (2013), Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment, Cancer Research 73(8): 2480-2492.
- Kaplon, J.; Zheng, L.; Meissl, K.; Chaneton, B.; Selivanov, V.A.; Mackay, G.; Burg, S.H. van der; Verdegaal, E.M.E.; Cascante, M.; Shlomi, T.; Gottlieb, E. & Peeper, D.S. (2013), A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence, Nature 498(7452): 109-+.
- Ly, L.V.; Sluijter, M.; Burg, S.H. van der; Jager, M.J. & Hall, T. van (2013), Effective Cooperation of Monoclonal Antibody and Peptide Vaccine for the Treatment of Mouse Melanoma, Journal of Immunology 190(1): 489-496.
- Rosalia, R.A.; Quakkelaar, E.D.; Redeker, A.; Khan, S.; Camps, M.; Drijfhout, J.W.; Silva, A.L.; Jiskoot, W.; Hall, T. van; Veelen, P.A. van; Janssen, G.; Franken, K.; Cruz, L.J.; Tromp, A.; Oostendorp, J.; derBurg, S.H. van; Ossendorp, F. & Melief, C.J.M. (2013), Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation, European Journal of Immunology 43(10): 2554-2565.
- Burg, S.H. van der; Dijkgraaf, E.M.; Weiters, M.J.P. & Kroep, J.R. (2013), Chemotherapy-enhanced NFkB pathway activation in gynecological cancers increases the differentiation of monocytes to M2 macrophages instead of dendritic cells., Cancer Research 73(8).
- Esch, E.M.G. van; Dam, M.C.I.; Osse, M.E.M.; Putter, H.; Trimbos, B.J.B.M.Z.; Fleuren, G.; Burg, S.H. van der & Poelgeest, M.I.E. van (2013), Clinical Characteristics Associated With Development of Recurrence and Progression in Usual-Type Vulvar Intraepithelial Neoplasia, International Journal of Gynecological Cancer 23(8): 1476-1483.
- Bronkhorst, I.H.G.; Jehs, T.M.L.; Dijkgraaf, E.M.; Luyten, G.P.M.; Velden, P.A. van der; Burg, S.H. van der & Jager, M.J. (2013), Effect of hypoxic stress on induction and plasticity of tumor-induced immune cells in uveal melanoma, Acta Ophthalmologica 91.
- Zeestraten, E.C.M.; Speetjens, F.M.; Welters, M.J.P.; Saadatmand, S.; Stynenbosch, L.F.M.; Jongen, R.; Kapiteijn, E.; Gelderblom, H.; Nijman, H.W.; Valentijn, A.R.P.M.; Oostendorp, J.; Fathers, L.M.; Drijfhout, J.W.; Velde, C.J.H. van de; Kuppen, P.J.K.; Burg, S.H. van der & Melief, C.J.M. (2013), Addition of interferon-alpha to the p53-SLP (R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: A phase I/II clinical trial.
- Schrevel, M.; Karim, R.; Haar, N.T. ter; Burg, S.H. van der; Trimbos, J.B.M.Z.; Fleuren, G.J.; Gorter, A. & Jordanova, E.S. (2012), CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients., British Journal of Cancer 106(9): 1520-5.
- Steenwijk, P.J.D. van; Ramwadhdoebe, T.H.; Lowik, M.J.G.; Minne, C.E. van der; Berends-van der Meer, D.M.A.; Fathers, L.M.; Valentijn, A.R.P.M.; Oostendorp, J.; Fleuren, G.J.; Hellebrekers, B.W.J.; Welters, M.J.P.; Poelgeest, M.I. van; Melief, C.J.M.; Kenter, G.G. & Burg, S.H. van der (2012), A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions, Cancer Immunology, Immunotherapy 61(9): 1485-1492.
- Welters, M.J.P.; Gouttefangeas, C.; Ramwadhdoebe, T.H.; Letsch, A.; Ottensmeier, C.H.; Britten, C.M. & Burg, S.H. van der (2012), Harmonization of the intracellular cytokine staining assay, Cancer Immunology, Immunotherapy 61(7): 967-978.
- Vermeij, R.; Leffers, N.; Hoogeboom, B.N.; Hamming, I.L.E.; Wolf, R.; Reyners, A.K.L.; Molmans, B.H.W.; Hollema, H.; Bart, J.; Drijfhout, J.W.; Oostendorp, J.; Zee, A.G.J. van der; Melief, C.J.; Burg, S.H. van der; Daemen, T. & Nijman, H.W. (2012), Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study.
- Esch, E.M.G. van; Welters, M.J.P.; Jordanova, E.S.; Trimbos, J.B.M.Z.; Burg, S.H. van der & Poelgeest, M.I.E. van (2012), Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy, Expert Review of Vaccines 11(7): 821-840.
- Dijkgraaf, E.M.; Welters, M.J.P.; Nortier, J.W.R.; Burg, S.H. van der & Kroep, J.R. (2012), Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer, Current Pharmaceutical Design 18(25): 3816-3827.
- Leffers, N.; Vermeij, R.; Hoogeboom, B.N.; Schulze, U.R.; Wolf, R.; Hamming, I.E.; Zee, A.G. van der; Melief, K.J.; Burg, S.H. van der; Daemen, T. & Nijman, H.W. (2012), Long-term clinical and immunological effects of p53-SLP (R) vaccine in patients with ovarian cancer.
- Hall, T. van; Burg, S.H. van der & Melief, C.J.M. (2012), Mechanisms of Peptide Vaccination in Mouse Models: Tolerance, Immunity, and Hyperreactivity, ADVANCES IN IMMUNOLOGY , VOL 114: SYNTHETIC VACCINES 114: 51-76.
- Singh, S.K.; Meyering, M.; Ramwadhdoebe, T.H.; Stynenbosch, L.F.M.; Redeker, A.; Kuppen, P.J.K.; Melief, C.J.M.; Welters, M.J.P. & Burg, S.H. van der (2012), The simultaneous ex vivo detection of low-frequency antigen-specific CD4+and CD8+T-cell responses using overlapping peptide pools, Cancer Immunology, Immunotherapy 61(11): 1953-1963.
- Britten, C.M.; Janetzki, S.; Butterfield, L.H.; Ferrari, G.; Gouttefangeas, C.; Huber, C.; Kalos, M.; Levitsky, H.I.; Maecker, H.T.; Melief, C.J.M.; O'Donnell-Tormey, J.; Odunsi, K.; Old, L.J.; Ottenhoff, T.H.M.; Ottensmeier, C.; Pawelec, G.; Roederer, M.; Roep, B.O.; Romero, P.; Burg, S.H. van der; Walter, S.; Hoos, A. & Davis, M.M. (2012), T Cell Assays and MIATA: The Essential Minimum for Maximum Impact, Immunity 37(1): 1-2.
- Bronkhorst, I.H.G.; Vu, T.H.K.; Jordanova, E.S.; Luyten, G.P.M.; Burg, S.H. van der & Jager, M.J. (2012), Different Subsets of Tumor-Infiltrating Lymphocytes Correlate with Macrophage Influx and Monosomy 3 in Uveal Melanoma, Investigative Ophthalmology & Visual Science 53(9): 5370-5378.
- Stern, P.L.; Burg, S.H. van der; Hampson, I.N.; Broker, T.R.; Fiander, A.; Lacey, C.J.; Kitchener, H.C. & Einstein, M.H. (2012), Therapy of Human Papillomavirus-Related Disease, Vaccine 30: F71-F82.
- Heusinkveld, M.; Goedemans, R.; Briet, R.J.P.; Gelderblom, H.; Nortier, J.W.R.; Gorter, A.; Smit, V.T.H.B.M.; Langeveld, A.P.M.; Jansen, J.C. & Burg, S.H. van der (2012), Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer., International Journal of Cancer.
- Scholten, K.B.J.; Turksma, A.W.; Ruizendaal, J.J.; Hende, M. van den; Burg, S.H. van der; Heemskerk, M.H.M.; Meijer, C.J.L.M. & Hooijberg, E. (2011), Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer, Journal of Translational Medicine 9.
- Gooden, M.; Lampen, M.; Jordanova, E.S.; Leffers, N.; Trimbos, J.B.; Burg, S.H. van der; Nijman, H. & Hall, T. van (2011), HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes, Proceedings of the National Academy of Sciences 108(26): 10656-10661.
- Karim, R.; Meyers, C.; Backendorf, C.; Ludigs, K.; Offringa, R.; Ommen, G.J.B. van; Melief, C.J.M.; Burg, S.H. van der & Boer, J.M. (2011), Human Papillomavirus Deregulates the Response of a Cellular Network Comprising of Chemotactic and Proinflammatory Genes, PLoS ONE 6(3).
- Vermeij, R.; Leffers, N.; Burg, S.H. van der; Melief, C.J.; Daemen, T. & Nijman, H.W. (2011), Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies, Journal of Biomedicine and Biotechnology.
- Burg, S.H. van der; Arens, R. & Melief, C.J.M. (2011), Immunotherapy for persistent viral infections and associated disease, Trends in Immunology 32(3): 97-103.
- Heusinkveld, M.; Steenwijk, P.J.D. van; Goedemans, R.; Ramwadhdoebe, T.H.; Gorter, A.; Welters, M.J.P.; Hall, T. van & Burg, S.H. van der (2011), M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4(+) Th1 Cells, Journal of Immunology 187(3): 1157-1165.
- Heusinkveld, M. & Burg, S.H. van der (2011), Identification and manipulation of tumor associated macrophages in human cancers, Journal of Translational Medicine 9: -.
- Britten, C.M.; Janetzki, S.; Burg, S.H. van der; Huber, C.; Kalos, M.; Levitsky, H.I.; Maecker, H.T.; Melief, C.J.M.; O'Donnell-Tormey, J.; Odunsi, K.; Old, L.J.; Pawelec, G.; Roep, B.O.; Romero, P.; Hoos, A. & Davis, M.M. (2011), Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond, Cancer Immunology, Immunotherapy 60(1): 15-22.
- Butterfield, L.H.; Palucka, A.K.; Britten, C.M.; Dhodapkar, M.V.; Hakansson, L.; Janetzki, S.; Kawakami, Y.; Kleen, T.O.; Lee, P.P.; Maccalli, C.; Maecker, H.T.; Maino, V.C.; Maio, M.; Malyguine, A.; Masucci, G.; Pawelec, G.; Potter, D.M.; Rivoltini, L.; Salazar, L.G.; Schendel, D.J.; Slingluff, C.L.; Song, W.R.; Stroncek, D.F.; Tahara, H.; Thurin, M.; Trinchieri, G.; Burg, S.H. van der; Whiteside, T.L.; Wigginton, J.M.; Marincola, F.; Khleif, S.; Fox, B.A. & Disis, M.L. (2011), Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers, Clinical Cancer Research 17(10): 3064-3076.
- Verdegaal, E.M.E.; Visser, M.; Ramwadhdoebe, T.H.; Minne, C.E. van der; Steijn, J.A.Q.M.J. van; Kapiteijn, E.; Haanen, J.B.A.G.; Burg, S.H. van der; Nortier, J.W.R. & Osanto, S. (2011), Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+and CD8+T cells in combination with low-dose interferon-alpha, Cancer Immunology, Immunotherapy 60(7): 953-963.
- Burg, S.H. van der & Melief, C.J.M. (2011), Therapeutic vaccination against human papilloma virus induced malignancies, Current Opinion in Immunology 23(2): 252-257.
- Burg, S.H. van der; Kalos, M.; Gouttefangeas, C.; Janetzki, S.; Ottensmeier, C.; Welters, M.J.P.; Romero, P.; Britten, C.M. & Hoos, A. (2011), Harmonization of Immune Biomarker Assays for Clinical Studies, Science Translational Medicine 3(108): -.
- Heusinkveld, M.; Welters, M.J.P.; Poelgeest, M.I.E. van; Hulst, J.M. van der; Melief, C.J.M.; Fleuren, G.J.J.; Kenter, G.G. & Burg, S.H. van der (2011), The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors, International Journal of Cancer 128(2): 379-389.
- Vermeij, R.; Bock, G.H. de; Leffers, N.; Hoor, K.A. ten; Schulze, U.; Hollema, H.; Burg, S.H. van der; Zee, A.G.J. van der; Daemen, T. & Nijman, H.W. (2011), Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression, Journal of Immunotherapy 34(6): 516-523.
- Pander, J.; Heusinkveld, M.; Straaten, T. van der; Jordanova, E.S.; Baak-Pablo, R.; Gelderblom, H.; Morreau, H.; Burg, S.H. van der; Guchelaar, H.J. & Hall, T. van (2011), Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab, Clinical Cancer Research 17(17): 5668-5673.
- Oliveira, C.C.; Querido, B.; Sluijter, M.; Derbinski, J.; Burg, S.H. van der & Hall, T. van (2011), Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires, European Journal of Immunology 41(11): 3114-3124.
- Speetjens, F.M.; Zeestraten, E.C.M.; Kuppen, P.J.K.; Melief, C.J.M. & Burg, S.H. van der (2011), Colorectal cancer vaccines in clinical trials, Expert Review of Vaccines 10(6): 899-921.
- Lampen, M.H.; Verweij, M.C.; Querido, B.; Burg, S.H. van der; Wiertz, E.J.H.J. & Hall, T. van (2010), CD8(+) T Cell Responses against TAP-Inhibited Cells Are Readily Detected in the Human Population, Journal of Immunology 185(11): 6508-6517.
- Piersma, S.J.; Hulst, J.M. van der; Kwappenberg, K.M.C.; Goedemans, R.; Minne, C.E. van der & Burg, S.H. van der (2010), Influenza matrix 1-specific human CD4(+) FOXP3(+) and FOXP3(-) regulatory T cells can be detected long after viral clearance, European Journal of Immunology 40(11): 3064-3074.
- Ly, L.V.; Sluijter, M.; Versluis, M.; Luyten, G.P.M.; Burg, S.H. van der; Melief, C.J.M.; Jager, M.J. & Hall, T. van (2010), Peptide Vaccination after T-Cell Transfer Causes Massive Clonal Expansion, Tumor Eradication, and Manageable Cytokine Storm, Cancer Research 70(21): 8339-8346.
- Kenter, G.G.; Burg, S.H. van der & Melief, C.J.M. (2010), Vaccination against HPV-16 for Vulvar Intraepithelial Neoplasia REPLY, New England Journal of Medicine 362(7): 656-656.
- Oliveira, C.C.; Veelen, P.A. van; Querido, B.; Ru, A. de; Sluijter, M.; Laban, S.; Burg, S.H. van der; Offringa, R. & Hall, T. van (2010), The nonpolymorphic MHC Qa-1(b) mediates CD8(+) T cell surveillance of antigen-processing defects, Journal of Experimental Medicine 207(1): 207-221.
- Dongen, M. van; Savage, N.D.L.; Jordanova, E.S.; Briaire-de Bruijn, I.H.; Walburg, K.V.; Ottenhoff, T.H.M.; Hogendoorn, P.C.W.; Burg, S.H. van der; Gelderblom, H. & Hall, T. van (2010), Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors, International Journal of Cancer 127(4): 899-909.
- Steenwijk, P.J.D. van; Heusinkveld, M.; Ramwadhdoebe, T.H.; Lowik, M.J.; Hulst, J.M. van der; Goedemans, R.; Piersma, S.J.; Kenter, G.G. & Burg, S.H. van der (2010), An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer, Cancer Research 70(7): 2707-2717.
- Moodie, Z.; Price, L.; Gouttefangeas, C.; Mander, A.; Janetzki, S.; Lower, M.; Welters, M.J.P.; Ottensmeier, C.; Burg, S.H. van der & Britten, C.M. (2010), Response definition criteria for ELISPOT assays revisited, Cancer Immunology, Immunotherapy 59(10): 1489-1501.
- Welters, M.J.P.; Kenter, G.G.; Steenwijk, P.J.D. van; Lowik, M.J.G.; Berends-van der Meer, D.M.A.; Essahsah, F.; Stynenbosch, L.F.M.; Vloon, A.P.G.; Ramwadhdoebe, T.H.; Piersma, S.J.; Hulst, J.M. van der; Valentijn, A.R.P.M.; Fathers, L.M.; Drijfhout, J.W.; Franken, K.L.M.C.; Oostendorp, J.; Fleuren, G.J.; Melief, C.J.M. & Burg, S.H. van der (2010), Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses, Proceedings of the National Academy of Sciences 107(26): 11895-11899.
- Mander, A.; Gouttefangeas, C.; Ottensmeier, C.; Welters, M.J.P.; Low, L.; Burg, S.H. van der & Britten, C.M. (2010), Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program, Cancer Immunology, Immunotherapy 59(4): 619-627.
- Janetzki, S.; Price, L.; Britten, C.M.; Burg, S.H. van der; Caterini, J.; Currier, J.R.; Ferrari, G.; Gouttefangeas, C.; Hayes, P.; Kaempgen, E.; Lennerz, V.; Nihlmark, K.; Souza, V. & Hoos, A. (2010), Performance of serum-supplemented and serum-free media in IFN gamma Elispot Assays for human T cells, Cancer Immunology, Immunotherapy 59(4): 609-618.
- Woo, Y.L.; Hende, M. van den; Sterling, J.C.; Coleman, N.; Crawford, R.A.F.; Kwappenberg, K.M.C.; Stanley, M.A. & Burg, S.H. van der (2010), A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6-and E7-specific T-cell responses, International Journal of Cancer 126(1): 133-141.
- Hende, M. van den; Redeker, A.; Kwappenberg, K.M.C.; Franken, K.L.M.C.; Drijfhout, J.W.; Oostendorp, J.; Valentijn, A.R.P.M.; Fathers, L.M.; Welters, M.J.P.; Melief, C.J.M.; Kenter, G.G.; Burg, S.H. van der & Offringa, R. (2010), Evaluation of Immunological Cross-Reactivity between Clade A9 High-Risk Human Papillomavirus Types on the Basis of E6-Specific CD4(+) Memory T Cell Responses, Journal of Infectious Diseases 202(8): 1200-1211.
- Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Van der Burg SH & Melief CJM (2009), Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia., New England Journal of Medicine 361(19): 1838-1847.
- Leffers N, Lambeck AJA, Gooden MJM, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PHB, Molmans BHW, Hollema H, Drijfhout JW, Valentijn ARPM, Fathers L, Oostendorp J, Van der Zee AG, Melief CJM, Van der Burg SH, Daemen T & Nijman HW (2009), Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial, International Journal of Cancer 125(9): 2104-2113.
- Weterings JJ, Khan S, van Noort GJV, Melief CJM, Overkleeft HS, van der Burg SH, Ossendorp F, van der Marel GA & Filippov DV (2009), 2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation, Bioorganic and Medicinal Chemistry Letters 19(8): 2249-2251.
- van der Burg SH & Palefsky JM (2009), Human immunodeficiency virus and human papilloma virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful, Journal of Translational Medicine 7.
- Khan S, Weterings JJ, Britten CM, de Jong AR, Graafland D, Melief CJM, van der Burg SH, van der Marel G, Overkleeft HS, Filippov DV & Ossendorp F (2009), Chirality of TLR-2 ligand Pam(3)CysSK(4) in fully synthetic peptide conjugates critically influences the induction of specific CD8(+) T-cells, Molecular Immunology 46(6): 1084-1091.
- Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen LP, Boer JM, Melief CJM & van der Burg SH (2009), Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma, Clinical Cancer Research 15(20): 6341-6347.
- Speetjens FM, Kuppen PK, Welters MJP, Essahsah F, van den Brink AMEGV, Lantrua MGK, Valentijn ARPM, Oostendorp J, Fathers LM, Nijman HW, Pander J, Drijfhout JW, Van de Velde CJH, Melief CJM & Van der Burg SH (2009), Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer, Clinical Cancer Research 15(3): 1086-1095.
- Lauwen MM, Zwaveling S, de Quartel L, Mota SCF, Grashorn JAC, Melief CJM, van der Burg SH & Offringa R (2008), Self-tolerance does not restrict the CD4+T-helper response against the p53 tumor antigen, Cancer Research 68(3).
- Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, Berends-van der Meer DMA, Vloon APG, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH & Melief CJM (2008), Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity, Clinical Cancer Research 14(1).
- Woo YL, Sterling J, Crawford R, van der Burg SH, Coleman N & Stanley M (2008), FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies, Journal of Clinical Pathology 61(8).
- Welters MJP, Kenter GG, Piersma SJ, Vloon APG, Lowik MJG, Berends-van der Meer DMA, Drijfhout JW, Valentijn ARPM, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJM & van der Burg SH (2008), Induction of tumor-specific CD4+ and CD8+ T-Cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine, Clinical Cancer Research 14(1).
- Bijker, M.S.; Eeden, S.J.E. van den; Franken, K.L.; Melief, C.J.M.; Burg, S.H. van der & Offringa, R. (2008), Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation, European Journal of Immunology 38(4).
- Melief CJM & van der Burg SH (2008), Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines, Nature Reviews Cancer 8(5).
- Piersma SJ, Welters MJP & van der Burg SH (2008), Tumor-specific regulatory T cells in cancer patients, Human Immunology 69(4-5).
- van Steenwijk PJD, Piersma SJ, Welters MJP, van der Hulst JM, Fleuren G, Hellebrekers BWJ, Kenter GG & van der Burg SH (2008), Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response, Clinical Cancer Research 14(22).
- Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH & Fleuren GJ (2008), Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8(+)/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients?, Clinical Cancer Research 14(7).
- van den Hende M, van Poelgeest MIE, van der Hulst JM, de Jong J, Drijfhout JW, Fleuren GJ, Valentijn ARPM, Wafelman AR, Slappendel GM, Melief CJM, Offringa R, van der Burg SH & Kenter GG (2008), Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia, International Journal of Cancer 123(1).
- Britten CM, Gouttefangeas C, Welters MJP, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus J, Haas I, Mackensen A, Kollgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Wolfel T & van der Burg SH (2008), The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays, Cancer Immunology, Immunotherapy 57(3).
- Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C & Hoos A (2008), Toward the harmonization of immune monitoring in clinical trials: Quo vadis?, Cancer Immunology, Immunotherapy 57(3).
- Speetjens FM, Kuppen PJK, Morreau H & van der Burg SH (2008), Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers, Gastroenterology 135(2).
- Welters MJP, Piersma SJ & van der Burg SH (2008), T-regulatory cells in tumour-specific vaccination strategies, Expert Opinion on Biological Therapy 8(9).
- van der Burg SH (2008), Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding, Expert Review of Vaccines 7(1).
- Woo YL, Sterling J, Damay I, Coleman N, Crawford R, van der Burg SH & Stanley M (2008), Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis, BJOG: An International Journal of Obstetrics and Gynaecology 115(13).
- Welters, M.J.P.; Bijker, M.S.; Eeden, S.J.F. van den; Franken, K.L.M.C.; Melief, C.J.M.; Offringa, R. & Burg, S.H. van der (2007), Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists, Vaccine 25(8).
- van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KMC, van den Hende M, Welters MJP, Van Rood JJ, Fleuren GJ, Melief CJM, Kenter GG & Offringa R (2007), Association of cervical cancer with the presence of CD4(+) regulatory T cells specific for human papillornavirus antigens, Proceedings of the National Academy of Sciences 104(29).
- Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, Wada T, Beissert S, Melief CJM & Penninger JM (2007), Spontaneous tumor rejection by cbl-b-deficient CD8(+) T cells, Journal of Experimental Medicine 204(4).
- de Boer MA, Jordanova ES, van Poelgeest MIE, van den Akker BE, van der Burg SH, Kenter GG & Fleuren GJ (2007), Circulating human papillomavirus Type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts, International Journal of Cancer 121(12).
- Bijker MS, Melief CJ, Offringa R & van der Burg SH (2007), Design and development of synthetic peptide vaccines: past, present and future, Expert Review of Vaccines 6(4).
- Weterings JJ, Khan S, Kriek NMA, van der Marel GA, Overkleeft HS, Ossendorp F, van der Burg SH, Drijfhout JW & Filippov DV (2007), Synthesis of modified and hybrid protein derived biopolymers, Biopolymers 88(4).
- Bijker, M.S.; Eeden, S.J.F. van den; Franken, K.L.; Melief, C.J.M.; Offringa, R. & Burg, S.H. van der (2007), CD8(+) CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity, Journal of Immunology 179(8).
- Bos R, Van Duikeren S, Van Hall T, Lauwen MM, Parrington M, Berinstein NL, McNeil B, Melief CJM, Verbeek JS, Van der Burg SH & Offringa R (2007), Characterization of antigen-specific immune responses induced by Canarypox virus Vaccines, Journal of Immunology 179(9).
- Khan S, Bijker MS, Weterings JJ, Tanke HJ, Adema GJ, van Hall T, Drijfhout JW, Melief CJM, Overkleeft HS, van der Marel GA, Filippov DV, van der Burg SH & Ossendorp F (2007), Distinct uptake mechanisms but similar intracellular processing of two different Toll-like receptor ligand-peptide conjugates in dendritic cells, Journal of Biological Chemistry 282(29).
- Mehta AM, Jordanova ES, van Wezel T, Uh HW, Corver WE, Kwappenberg KMC, Verduijn W, Kenter GG, van der Burg SH & Fleuren GJ (2007), Genetic variation of antigen processing machinery components and association with cervical carcinoma, Genes, Chromosomes and Cancer 46(6).
- Welters, M.J.P.; Bijker, M.S.; Eeden, S.J.F. van den; Franken, K.L.M.C.; Melief, C.J.M.; Offringa, R. & Burg, S.H. van der (2007), Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists (vol 25, pg 1379, 2007), Vaccine 25(41).
- Piersma SJ, Jordanova ES, van Poelgeest MIE, Kwappenberg KMC, van der Hulst JM, Drijfhout JW, Melief CJM, Kenter GG, Fleuren GJ, Offringa R & van der Burg SH (2007), High number of intraepithelial CD8(+) tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer, Cancer Research 67(1).
- Advies mbt investeringen in immunologische therapien ter bestrijding kanker
- Strategie advisory board